Tag: PARP inhibitors

Tag Visualization: Top 50 related tags by occurrence

Recent Related Articles to PARP inhibitors

FDA Clock Starts for AstraZeneca and Merck in Prostate Cancer, Roche in DLBCL

Added to Collection on: 2022-08-16 14:08:32

Tags for this article:

RTT
Drugs
Organic compounds
Cancer
Prodrugs
Lactams
PARP inhibitors
AstraZeneca
Prostate cancer
Genentech
Olaparib
Prednisone

Click the tags to see associated articles and topics

View Article Details
TOP NEWS: AstraZeneca to present cancer drug data at oncology congress - Morningstar

Added to Collection on: 2022-08-24 09:05:49

Tags for this article:

Organic compounds
Chemical compounds
Cancer
PARP inhibitors
Oncology
RTT
Lactams
Indoles
Olaparib
AstraZeneca
Treatment of cancer
Poly (ADP-ribose) polymerase
AstraZeneca plc

Click the tags to see associated articles and topics

View Article Details
Lynparza approved in Japan for early breast cancer - AstraZeneca - Cision News

Added to Collection on: 2022-08-25 06:08:23

Tags for this article:

Breast cancer
Cancer
RTT
Health
Hereditary cancers
Clinical medicine
PARP inhibitors
Triple-negative breast cancer
Olaparib
BRCA mutation
Prostate cancer
Metastatic breast cancer
Japan
AstraZeneca plc

Click the tags to see associated articles and topics

View Article Details
SOLO1: Olaparib Maintenance Continues to Provide Clinical Benefit at 7 Years

Added to Collection on: 2022-09-10 16:40:15

Tags for this article:

PARP inhibitors
Cancer
Lactams
AstraZeneca
Olaparib
Phthalazines
Companies
Health
RTT
Ovarian cancer
BRCA mutation

Click the tags to see associated articles and topics

View Article Details
PARP rivals close in on AZ and Merck's market leading Lynparza - - Pharmaphorum

Added to Collection on: 2022-10-04 18:29:25

Tags for this article:

Organic compounds
Chemical compounds
Cancer
Lactams
PARP inhibitors
Prostate cancer
Rucaparib
Enzalutamide
Olaparib
Abiraterone acetate
MCRPC
Chemotherapy
Pfizer
Clovis Oncology

Click the tags to see associated articles and topics

View Article Details
Senhwa Announces First Patient Successfully Dosed in Phase I Study of Pindnarulex in ...

Added to Collection on: 2022-11-01 07:48:32

Tags for this article:

Cancer
Branches of biology
Organic compounds
Lactams
PARP inhibitors
RTT
Breast cancer
Tumor suppressor genes
Rucaparib
Synthetic lethality
Prostate cancer
BRCA1
Australia
Senhwa Biosciences Inc.
SAN DIEGO

Click the tags to see associated articles and topics

View Article Details
FDA Extends Review Period For AstraZeneca-Merck Partnered Cancer Drug ... - Yahoo Finance

Added to Collection on: 2022-12-15 13:24:03

Tags for this article:

Drugs
RTT
Chemical compounds
Hormones
Glucocorticoids
Mineralocorticoids
Prostate cancer
PARP inhibitors
Olaparib
Merck & Co.
MCRPC
Prednisone

Click the tags to see associated articles and topics

View Article Details
PARP Inhibitor Market Future Business Opportunities 2022-2028 - Digital Journal

Added to Collection on: 2022-12-25 16:37:35

Tags for this article:

Organic compounds
Chemical compounds
Business
Lactams
PARP inhibitors
Market structure
Programmed cell death
DNA repair
Poly (ADP-ribose) polymerase
Olaparib
Market research
Rucaparib

Click the tags to see associated articles and topics

View Article Details
Pfizer Announces Positive Top-Line Results from Phase 3 Study of ... - Investing News Network

Added to Collection on: 2022-12-29 23:50:31

Tags for this article:

Medicine
Clinical medicine
Cancer
Cancer treatments
RTT
Oncology
Lactams
PARP inhibitors
Adjuvant therapy
Olaparib
Chemotherapy
Prostate cancer
abiraterone
United States

Click the tags to see associated articles and topics

View Article Details
Olaparib by AstraZeneca for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

Added to Collection on: 2023-10-27 23:15:17

Tags for this article:

Orphan drugs
PARP inhibitors
Gynaecological cancer
Infectious causes of cancer
Breakthrough therapy
Olaparib
Bevacizumab
Ovarian cancer
Cancer
Breast cancer
Triple-negative breast cancer
Non-small-cell lung cancer

Click the tags to see associated articles and topics

View Article Details